Ventyx Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Ventyx Biosciences has a total shareholder equity of $278.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $301.1M and $22.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$274.83m |
| Equity | US$278.77m |
| Total liabilities | US$22.33m |
| Total assets | US$301.10m |
Recent financial health updates
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully
Nov 14
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
Jul 12Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation
Feb 15Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth
Sep 21Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
Feb 20Recent updates
We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth Carefully
Nov 14Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Nov 04Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?
Jul 12Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade)
Jul 01Ventyx Pivots To Obesity Amid Transformation
Mar 12Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Situation
Feb 15Ventyx: Too Risky Right Now After Some Poor Data
Jan 18Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In Growth
Sep 21Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
Feb 20Ventyx Biosciences: Not Chasing This Rally
Sep 18We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth
Aug 19Ventyx Biosciences GAAP EPS of -$0.39 beats by $0.06
Aug 15Ventyx Biosciences autoimmune/autoinflammatory candidate meets phase 1 goals
Jun 29We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate
May 06We Think Ventyx Biosciences (NASDAQ:VTYX) Can Afford To Drive Business Growth
Jan 21Financial Position Analysis
Short Term Liabilities: VTYX's short term assets ($289.4M) exceed its short term liabilities ($12.3M).
Long Term Liabilities: VTYX's short term assets ($289.4M) exceed its long term liabilities ($10.0M).
Debt to Equity History and Analysis
Debt Level: VTYX is debt free.
Reducing Debt: VTYX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VTYX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VTYX has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 54.4% each year.